Commentary: On the levels of patient selection in registry-based randomized controlled trials

被引:0
作者
Florian Lasch
Kristina Weber
Armin Koch
机构
[1] Hannover Medical School,Department of Biostatistics
[2] F. Hoffmann-La Roche AG,undefined
[3] MDBD,undefined
来源
Trials | / 20卷
关键词
Registry; Registry-based RCT; Patient selection; Pragmatic trials; Generalizability; External validity;
D O I
暂无
中图分类号
学科分类号
摘要
Registry-based randomized controlled trials (RCTs) are presumed to include a less-selected patient population and thus to have enhanced generalizability compared to conventional RCTs. However, this view disregards the levels of patient selection in registry-based RCTs: the registry selection level and the trial selection level. At both levels, systematic selection can occur and generalizability can be diminished. Nevertheless, using a registry as a basis for recruitment, randomization, and data collection results in an advantage: the trial selection takes place within the registry framework, where baseline characteristics of non-enrolled patients are automatically documented as well. By comparing the baseline variables of the enrolled and non-enrolled patients, the trial selection can always be investigated, which gives a sound basis for discussing the generalizability to the registry population.
引用
收藏
相关论文
共 141 条
  • [1] Laurer MS(2013)The Randomized Registry Trial — the next disruptive technology in clinical research? N Engl J Med 369 1579-1581
  • [2] D’Agostino RB(2015)Registry-based randomized clinical trials - a new clinical trial paradigm Nat Rev Cardiol 12 312-316
  • [3] James S(2016)Registry-based randomized controlled trials- what are the advantages, challenges, and areas for future research? J Clin Epidemiol 80 16-24
  • [4] Rao SV(2017)Registry-based pragmatic trials in heart failure: current experience and future directions Curr Heart Fail Rep 14 59-70
  • [5] Granger CB(2006)Factors that can affect the external validity of randomised controlled trials PLoS Clin Trials 1 e9-93
  • [6] Li G(2005)External validity of randomised controlled trials: “to whom do the results of this trial apply?” Lancet 365 82-94
  • [7] Sajobi TT(2010)How to assess the external validity of therapeutic trials: A conceptual approach Int J Epidemiol 39 89-1085
  • [8] Menon BK(2013)Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): An open-label, randomised phase 3 trial Lancet Oncol 14 1077-119
  • [9] Korngut L(2016)2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Eur Heart J 37 67-922
  • [10] Lowerison M(2015)Register or electronic health records enriched randomized pragmatic trials: The future of clinical effectiveness and cost-effectiveness trials? Nord J Heal Econ 5 62-42